Navigation Links
NeoStem Announces Participation in Multiple September Conferences
Date:9/8/2011

NEW YORK, Sept. 8, 2011 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with a focus on cell-based therapeutic development, today announced it is presenting at three upcoming September conferences: the Rodman & Renshaw Annual Healthcare Conference, the Cell Therapy Commercialization Summit, and the JMP Securities Healthcare Conference.

"NeoStem's strategic combination of revenues with manufacturing and a global reach has positioned the Company to be a leader in the cell therapy space and we are pleased to share NeoStem updates with industry and the investor community," said Dr. Robin L. Smith, Chairman and CEO of NeoStem.  NeoStem will be presenting at the following conferences:

Rodman & Renshaw 13th Annual Healthcare Conference - September 11-13, New York, New York

11:15 AM on Monday, September 12 at the Waldorf Astoria, New York, NY in the Starlight North room.

Cell Therapy Commercialization Summit - September 19-21, Boston, MA

11 AM on Monday, September 19 as part of the Cell Therapy Investor Forum, located in the Seaport World Trade Center.

1:45 PM and 4:30 PM on Tuesday, September 20.

6th Annual JMP Securities Healthcare Conference - September 27-29, New York, New York

Wednesday, September 28 at 9 AM at the St. Regis Hotel, New York, NY.

About NeoStem, Inc.

NeoStem is engaged in the development and manufacturing of cell-based therapies in the U.S. Its January, 2011 acquisition of Progenitor Cell Therapy, and its July 13, 2011 agreement to acquire Amorcyte, Inc. (which is expected to close in the fourth quarter subject to shareholder approval) position NeoStem to achieve its mission of capturing the paradigm shift to cell therapy.

PCT not only gives NeoStem access to a world class contract manufacturing cell therapy company, but provides NeoStem a platform and expertise around the evaluation, development and regulatory requirements necessary to develop autologous, allogeneic, immunomodulatory and vaccine-based therapeutics.

NeoStem also holds the worldwide exclusive license to VSEL™ Technology, which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem owns 80% of Athelos Corporation, a company developing a T-cell therapeutic with potential in a range of auto-immune conditions such as graft versus host disease, asthma and diabetes. NeoStem's acquisition of Amorcyte, once the transaction is completed, will give the Company a Phase II asset for the treatment of acute myocardial infarctions and a Phase I asset for congestive heart failure. NeoStem will own 100% of the worldwide rights to the Amorcyte programs.

Furthermore, NeoStem is building its Chinese presence by establishing an operations lab for cell-based manufacturing in Beijing and is commercializing cellular therapies in China through the establishment of relationships with a network of hospitals.

NeoStem also owns a majority interest in Suzhou Erye Pharmaceutical Company Limited, a world class manufacturer and distributor of generic antibiotics in China, with reported revenues of $69 million in 2010.

For more information on NeoStem, please visit www.neostem.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 6, 2011, its Form 8-K filed on July 14, 2011 as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

For more information, please contact:

NeoStem, Inc.
Robin Smith, CEO
Phone: +1-212-584-4174
Email: rsmith@neostem.com
Web:   http://www.neostem.com


'/>"/>
SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeoStem Appoints Grant Thornton LLP as New Independent Registered Public Accounting Firm
2. NeoStem Provides Update on Amorcyte Clinical Progress and Reports Results for Second Quarter
3. NeoStem Announces Pricing of Public Offering for $16,500,000 in Gross Proceeds
4. NeoStem Announces Proposed Public Offering of Common Stock
5. NeoStem Signs Definitive Merger Agreement to Acquire Amorcyte in Equity Transaction
6. NeoStem Announces Agreement with Nankai Hospital in Tianjin to Offer NeoStems Licensed Orthopedic Technology
7. NeoStems Suzhou Erye Pharmaceutical Receives Two Awards at the Chempharm Brand Summit 2011
8. NeoStems Subsidiary Progenitor Cell Therapy Receives FACT Accreditation for Its New Allendale, New Jersey Manufacturing Facility
9. NeoStem to Present at 10th Annual Needham Healthcare Conference on Tuesday, April 5
10. NeoStem Provides Results for 2010 and an Update on Recent Activities
11. NeoStem To Present at Rodman & Renshaw Annual China Investment Conference on Tuesday, March 8
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... , Feb. 9, 2016  The Parenteral Drug ... professionals developing and manufacturing sterile drug products, today ... Regulatory Guidance Comparison – With link to Comparison ... issued by the U.S. FDA, the EU, the ... --> --> ...
(Date:2/8/2016)... , Feb.8, 2016 Alzheimer Diagnostic Tests ... Medical Devices sector report , "Alzheimer ... provides an overview of Alzheimer Diagnostic Tests currently ... information on the pipeline products with comparative analysis ... The report reviews major players involved in the ...
(Date:2/8/2016)... Cardiovascular Surgery Devices - Medical Devices Pipeline Assessment, ... report, "Cardiovascular Surgery Devices - Medical Devices Pipeline ... Devices currently in pipeline stage. ... comprehensive information on the pipeline products with comparative ... development. The report reviews major players involved in ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 2016 , ... Ross A. Clevens, MD, FACS , ... a new addition to their growing practice. Beginning this month, Teresa Imperiale-Westerfield, a ... performing cosmetic procedures including injectables, fillers and laser treatments. A master ...
(Date:2/10/2016)... TN (PRWEB) , ... February 09, 2016 , ... ... to sports concussion, yet the cause of injury may be one of many ... two-day advanced PT Continuing Education Course , Mastering Rehab Solutions for ...
(Date:2/9/2016)... ... February 09, 2016 , ... Steven Douglas Associates is a ... Florida Event, an upscale fundraiser held in South Florida. The Inaugural What’s Your Taste ... This year the event will be held in a new, more causal format at ...
(Date:2/9/2016)... Worth, Texas (PRWEB) , ... February 09, 2016 ... ... and reconstruction firm helping businesses recover after a disaster, announced today the acquisition ... service companies in Hawaii. , “Investing in like-minded companies who excel ...
(Date:2/9/2016)... ... February 09, 2016 , ... URise Products ... newest mobility device, the StandUp Walker. Made entirely in the USA, the StandUp ... 50 years. , StandUp Walker’s novel patent-pending design offers 2-in-1 benefits of ...
Breaking Medicine News(10 mins):